Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction: RIVAWAR, An Open-Label RCT.

ABSTRACT:

Background

Vitamin K antagonists, such as warfarin, are the standard treatment for left ventricular thrombus (LVT). However, direct oral anticoagulants, such as rivaroxaban, are increasingly being considered due to their fixed dosing and lack of routine monitoring requirements.

Objectives

This study aimed to compare the effectiveness of rivaroxaban vs warfarin in treating post-myocardial infarction (MI) acute LVT at 12 weeks.

Methods

We conducted an open-label, noninferiority, randomized controlled trial involving patients with acute LVT diagnosed during initial MI hospitalization. Participants were randomized 2:1 to receive either rivaroxaban (20 mg daily) or warfarin (target international normalized ratio 2-3) for 12 weeks. The primary endpoint, LVT resolution, was

SUBMITTER: Shah JA 

PROVIDER: S-EPMC12309278 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature